IN2015DN00139A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN00139A IN2015DN00139A IN139DEN2015A IN2015DN00139A IN 2015DN00139 A IN2015DN00139 A IN 2015DN00139A IN 139DEN2015 A IN139DEN2015 A IN 139DEN2015A IN 2015DN00139 A IN2015DN00139 A IN 2015DN00139A
- Authority
- IN
- India
- Prior art keywords
- domain
- car
- human
- antigen binding
- methods
- Prior art date
Links
- 230000011664 signaling Effects 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261671508P | 2012-07-13 | 2012-07-13 | |
PCT/US2013/050293 WO2014012001A2 (en) | 2012-07-13 | 2013-07-12 | Use of cart19 to deplete normal b cells to induce tolerance |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN00139A true IN2015DN00139A (ja) | 2015-06-12 |
Family
ID=49916701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN139DEN2015 IN2015DN00139A (ja) | 2012-07-13 | 2013-07-12 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20150290244A1 (ja) |
EP (1) | EP2872184B1 (ja) |
JP (4) | JP2015523386A (ja) |
KR (1) | KR102216083B1 (ja) |
CN (1) | CN104884095A (ja) |
AU (3) | AU2013289984B2 (ja) |
BR (1) | BR112015000657B1 (ja) |
CA (1) | CA2876734A1 (ja) |
EA (2) | EA201992742A3 (ja) |
ES (1) | ES2835232T3 (ja) |
IN (1) | IN2015DN00139A (ja) |
MX (2) | MX2015000433A (ja) |
WO (1) | WO2014012001A2 (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
RU2019137208A (ru) | 2013-02-20 | 2020-02-19 | Новартис Аг | ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII |
ES2814962T3 (es) | 2013-02-20 | 2021-03-29 | Novartis Ag | Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123 |
EP3623380A1 (en) | 2013-03-15 | 2020-03-18 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
RU2714902C2 (ru) | 2013-12-19 | 2020-02-20 | Новартис Аг | Химерные рецепторы антигена против мезотелина человека и их применение |
JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
KR20240042250A (ko) | 2014-04-07 | 2024-04-01 | 노파르티스 아게 | 항-cd19 키메라 항원 수용체를 사용한 암의 치료 |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
RU2741120C2 (ru) | 2014-07-21 | 2021-01-22 | Новартис Аг | Лечение рака с использованием химерного антигенного рецептора cll-1 |
CN107109419B (zh) | 2014-07-21 | 2020-12-22 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
WO2016028879A1 (en) * | 2014-08-19 | 2016-02-25 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating immune response |
EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
JP6815992B2 (ja) | 2014-10-08 | 2021-01-20 | ノバルティス アーゲー | キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用 |
IL303247A (en) | 2014-12-29 | 2023-07-01 | Novartis Ag | Methods for preparing cells expressing a chimeric receptor antigen |
WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
US11896614B2 (en) | 2015-04-17 | 2024-02-13 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
EP3461337A1 (en) | 2015-05-06 | 2019-04-03 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
WO2017015427A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
EP3858388A1 (en) * | 2015-09-28 | 2021-08-04 | Regents of the University of Minnesota | Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity |
CN109069597A (zh) | 2015-12-22 | 2018-12-21 | 诺华股份有限公司 | 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗 |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
SG11201809041TA (en) * | 2016-04-15 | 2018-11-29 | Novartis Ag | Compositions and methods for selective protein expression |
CN109328230A (zh) * | 2016-04-15 | 2019-02-12 | 宾夕法尼亚大学董事会 | 嵌合同种异体抗原受体t细胞的组合物和方法 |
GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
JP7062640B2 (ja) * | 2016-07-29 | 2022-05-06 | ジュノー セラピューティクス インコーポレイテッド | 抗cd19抗体に対する抗イディオタイプ抗体 |
CN117866991A (zh) | 2016-10-07 | 2024-04-12 | 诺华股份有限公司 | 用于治疗癌症的嵌合抗原受体 |
EP3548047A4 (en) * | 2016-11-30 | 2020-07-01 | Intrexon Corporation | STEROID ADMINISTRATION AND IMMUNOTHERAPY |
EP3346001A1 (en) * | 2017-01-06 | 2018-07-11 | TXCell | Monospecific regulatory t cell population with cytotoxicity for b cells |
US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
CN110832075A (zh) | 2017-03-22 | 2020-02-21 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
CN112203725A (zh) | 2018-06-13 | 2021-01-08 | 诺华股份有限公司 | Bcma嵌合抗原受体及其用途 |
US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
CN115151275A (zh) | 2019-08-30 | 2022-10-04 | 耶鲁大学 | 用于向细胞递送核酸的组合物和方法 |
AR120563A1 (es) | 2019-11-26 | 2022-02-23 | Novartis Ag | Receptores de antígeno quimérico cd19 y cd22 y sus usos |
CN114269902A (zh) * | 2019-12-27 | 2022-04-01 | 昭泰英基生物医药(香港)有限公司 | 一种工程化免疫杀伤细胞、其制备方法及应用 |
CA3162074A1 (en) * | 2020-01-10 | 2021-07-15 | Joseph HORVATINOVICH | Methods of treating tumors |
US20230265214A1 (en) | 2020-08-31 | 2023-08-24 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070102670A (ko) * | 2004-11-17 | 2007-10-19 | 앤지오젠 파마슈티칼스 피티와이. 리미티드 | B 세포 기능 조절방법 |
FR2879204B1 (fr) * | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
EP1795588A1 (en) * | 2005-12-07 | 2007-06-13 | Cellerix, S.L. | Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease |
CN102413839A (zh) * | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | 人源化抗cd19抗体制剂 |
US9181527B2 (en) * | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
US9133436B2 (en) * | 2010-02-04 | 2015-09-15 | The Trustees Of The University Of Pennsylvania | ICOS critically regulates the expansion and function of inflammatory human Th17 cells |
BR122021026169B1 (pt) * | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
ES2791716T3 (es) * | 2010-12-14 | 2020-11-05 | Univ Maryland | Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer |
-
2013
- 2013-07-12 AU AU2013289984A patent/AU2013289984B2/en active Active
- 2013-07-12 IN IN139DEN2015 patent/IN2015DN00139A/en unknown
- 2013-07-12 BR BR112015000657-4A patent/BR112015000657B1/pt active IP Right Grant
- 2013-07-12 JP JP2015521846A patent/JP2015523386A/ja not_active Withdrawn
- 2013-07-12 KR KR1020157002826A patent/KR102216083B1/ko active IP Right Grant
- 2013-07-12 EP EP13816739.0A patent/EP2872184B1/en active Active
- 2013-07-12 CA CA2876734A patent/CA2876734A1/en active Pending
- 2013-07-12 US US14/413,100 patent/US20150290244A1/en not_active Abandoned
- 2013-07-12 ES ES13816739T patent/ES2835232T3/es active Active
- 2013-07-12 EA EA201992742A patent/EA201992742A3/ru unknown
- 2013-07-12 EA EA201590209A patent/EA034644B1/ru not_active IP Right Cessation
- 2013-07-12 WO PCT/US2013/050293 patent/WO2014012001A2/en active Application Filing
- 2013-07-12 MX MX2015000433A patent/MX2015000433A/es unknown
- 2013-07-12 CN CN201380037500.6A patent/CN104884095A/zh active Pending
-
2015
- 2015-01-09 MX MX2018009820A patent/MX2018009820A/es unknown
-
2018
- 2018-04-23 JP JP2018082149A patent/JP2018135363A/ja not_active Withdrawn
- 2018-05-29 AU AU2018203756A patent/AU2018203756B2/en active Active
- 2018-06-04 US US15/996,667 patent/US20180271907A1/en not_active Abandoned
-
2020
- 2020-01-16 AU AU2020200315A patent/AU2020200315B2/en active Active
- 2020-07-01 JP JP2020113687A patent/JP2020158541A/ja not_active Withdrawn
-
2022
- 2022-09-22 JP JP2022150897A patent/JP2022173331A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EA201992742A2 (ru) | 2020-09-30 |
KR20150030750A (ko) | 2015-03-20 |
AU2013289984A1 (en) | 2015-01-22 |
BR112015000657A2 (pt) | 2017-06-27 |
JP2020158541A (ja) | 2020-10-01 |
EP2872184B1 (en) | 2020-09-16 |
WO2014012001A3 (en) | 2015-04-23 |
US20180271907A1 (en) | 2018-09-27 |
MX2015000433A (es) | 2016-04-28 |
CA2876734A1 (en) | 2014-01-16 |
EA034644B1 (ru) | 2020-03-02 |
EP2872184A2 (en) | 2015-05-20 |
AU2013289984B2 (en) | 2018-03-08 |
AU2020200315B2 (en) | 2021-11-04 |
EA201590209A1 (ru) | 2015-08-31 |
KR102216083B1 (ko) | 2021-02-17 |
US20150290244A1 (en) | 2015-10-15 |
JP2022173331A (ja) | 2022-11-18 |
AU2018203756B2 (en) | 2019-10-24 |
JP2018135363A (ja) | 2018-08-30 |
AU2018203756A1 (en) | 2018-06-21 |
JP2015523386A (ja) | 2015-08-13 |
WO2014012001A2 (en) | 2014-01-16 |
ES2835232T3 (es) | 2021-06-22 |
EA201992742A3 (ru) | 2020-12-30 |
BR112015000657A8 (pt) | 2018-01-16 |
BR112015000657B1 (pt) | 2023-12-05 |
MX2018009820A (es) | 2022-08-24 |
EP2872184A4 (en) | 2016-03-30 |
AU2020200315A1 (en) | 2020-02-06 |
CN104884095A (zh) | 2015-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN00139A (ja) | ||
IN2014DN07414A (ja) | ||
MX347078B (es) | Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer. | |
IN2014DN11155A (ja) | ||
IN2014DN06522A (ja) | ||
MX2018005618A (es) | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. | |
IL285475A (en) | Antibodies against dendritic cell antigen 2 of blood and uses thereof | |
MX2014010183A (es) | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. | |
PH12015500196B1 (en) | Methods of treating a tauopathy | |
MX2016004420A (es) | Proteinas de union especificas duales dirigidas contra los receptores de células inmunes y autoantígenos de señalización de tlr. | |
MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. | |
TN2013000246A1 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
TN2014000207A1 (en) | Anti il-36r antibodies |